Science Portrait: Prof. Fuyuhiko Tamanoi

Prof. Fuyuhiko Tamanoi received his PhD in Molecular Biology from Nagoya University in 1977 working under Profs. Reiji Okazaki and Tsuneko Okazaki. His work involved discontinuous replication of Bacillus subtilis DNA and uracil incorporation into DNA.

After this, he made an impressive career in the US. First, he carried out postdoctoral work on phage DNA replication at Harvard Medical School (1977-1980) working under Dr. Charles C. Richardson. He then worked at Cold Spring Harbor Laboratory (1980-1985) as a staff investigator. His scientific contribution includes elucidation of the initiation of adenovirus DNA replication.

He then moved to the University of Chicago as an Assistant Professor and established a group working on the molecular biology of cancer focusing on the RAS oncogene (1985-1993). His contribution includes the identification of a negative regulator of RAS called NF1, a product of neurofibromatosis type 1 gene. He also elucidated C-terminal modification and membrane association of RAS proteins. 

He continued his work on Cancer Research at the University of California, Los Angeles where he moved in 1994, and he became Professor there in 1997. He established the Signal Transduction program at the Jonsson Comprehensive Cancer Center in 1997 and directed research till 2017. He continues his affiliation at UCLA as a cross-appointment Professor in the Dept. of Microbiology and Molecular Genetics.

In 2017, he was appointed as a cross-appointment Professor at the Institute for Advanced Study at Kyoto University. In 2019, he established the Quantum Nano Medicine Research Center at the Institute for Integrated Cell-Material Sciences at Kyoto University.

When Professor Toshiharu Nagatsu looked for a former student of Professor Tsuneko Okazaki to give us a webinar in dedication to her, Professor Tamanoi kindly volunteered. He will talk about his time in the Okazaki lab, about Okazaki fragments, and his own continued work on DNA replication and cancer. As for the latter, it is quite exciting how with a combination of X-ray irradiation and nanotechnology their group can intoduce DNA breaks specifically into cancer cells. Please all attend this special and exciting webinar.

MY SCIENCE

(descriptions of his science by Prof. Tamanoi)

Nanoparticles and Nanomedicine

My work on nanoparticles was initiated more than ten years ago when we established an interdisciplinary center called “Nanomachine Center for Targeted Delivery and On-command Release” at the California NanoSystems Institute (CNSI) at UCLA. Our aim was to develop nanomachines for medical applications using mesoporous silica nanoparticles (MSN) as a base material. Our collaborative activity with Dr. Jeffrey Zink and Dr. Fraser Stoddart led to the development of nanovalves and nanoimpellers. I also served as the Research Director of CNSI for two years coordinating research on various aspects of nanotechnology. In our work on mesoporous silica nanoparticle (MSN) that represents our long-standing collaboration with Dr. Zink, we have shown that MSN provides an attractive carrier for anticancer drugs due to its large surface area and also because of its versatile feature to enable various chemical modifications. We have developed MSNs that release anticancer drugs in response to pH change, light and magnetic field stimulation (controlled release). We have also shown that MSNs can deliver siRNA to shut down gene expression. Operation of these MSN was evaluated in cancer cells, mouse models and chicken egg tumor models. More recently, we have developed a new type of nanoparticles called BPMO (biodegradable periodic mesoporous organosilica) nanoparticles. These are synthesized by incorporating biodegradable linkages such as tetrasulfide bonds into the framework of the nanoparticle. They are degraded by reducing conditions inside the body. BPMOs provide a promising type of nanomaterials for clinical application.

Signal Transduction and Cancer Therapy

My work also encompasses topics concerning signal transduction and anticancer drug development. My work on signal transduction was initiated when I was at Cold Spring Harbor Laboratory working on the RAS oncogenes and continued at the University of Chicago where I studied membrane association of RAS proteins. We have also worked on other members of the RAS superfamily G-proteins including RHEB that is an activator of mTOR (mammalian Target of Rapamycin). Our work on cancer therapy is focused on an approach to inhibit membrane association of the RAS superfamily proteins. We were one of the first groups to identify and characterize protein farnesyltransferase and protein geranylgeranyltransferases that facilitate the membrane association. We were also one of the first groups to identify small molecule inhibitors of protein farnesyltransferase; we identified natural compounds as the inhibitors. At UCLA, I continued to work on the development of farnesyltransferase inhibitors. More recently, we have developed novel GGTI, inhibitors of protein geranylgeranyltransferase type I. Antitumor activity of GGTI was demonstrated using animal model systems. From 1996 to 2017, I directed the Signal Transduction and Therapeutics program at Jonsson Comprehensive Cancer Center.

High Z element containing Nanoparticles and Radiation Therapy

Irradiation of high Z elements such as gold, silver, gadolinium and iodine to monochromatic X-rays results in photoelectric effect. If the X-ray energy is higher than the K-edge energy of the element, electrons in the K-shell are kicked out resulting in the Auger cascade and the release of Auger electrons. Since these low-energy electrons have a strong DNA damaging effect and cell killing, we have been investigating ways to use this approach for cancer therapy. We first prepared mesoporous silica nanoparticles containing gadolinium. They were incubated with tumor spheroids and then exposed to a monochromatic X-ray with 50.25 keV energy generated at the Spring-8 synchrotron. We have observed efficient destruction of the tumor spheroids and this was dependent on the energy level of the monochromatic X-ray. More recently, we developed iodine-containing nanoparticles that can be efficiently taken up into tumor spheroids. Irradiation with 33.2 keV monochromatic X-ray led to the generation of DNA double-strand breaks and the destruction of tumor spheroids. Our approach may lead to the development of a new type of radiation therapy.

CURRICULUM VITAE

EDUCATION:

Education and Training:

Tokyo University, Tokyo, Japan                  B.S.                     1972      Biochemistry

Tokyo University, Tokyo, Japan                  M.S.                    1974      Biochemistry

Nagoya University, Nagoya, Japan              Ph.D.                  1977      Molecular Biology

Harvard Medical School, Boston, MA.         Postdoc              1978      Biochemistry

PROFESSIONAL EXPERIENCE:

Academic Appointments:

2017 – Present      Professor, Institute for Advanced Study, Kyoto University, Japan

2017 – Present     Professor (cross-appointment), Dept. of MIMG, UCLA

1997 – 2017           Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles (UCLA)

1993 – 1997           Associate Professor, Department of Microbiology and Molecular Genetics, University of California, Los Angeles (UCLA)

1992 – 1993           Associate Professor, Department of Biochemistry and Molecular Biology, the University of Chicago

1985 – 1992           Assistant Professor, Department of Biochemistry and Molecular Biology, The University of Chicago

1982 – 1985      Joint Lab Chief, DNA Synthesis Section, Cold Spring Harbor Laboratory, NY

1982 – 1985           Senior Staff Investigator, Cold Spring Harbor Laboratory, NY

1980 – 1982           Staff Investigator, Cold Spring Harbor Laboratory, NY

1980                      EMBO Short Term Fellow, Institute for Genetics, University of Cologne

2015 – 2016          Visiting Professor, Tokushima University

2010 – 2012          Visiting Professor, Waseda University                 

2003 – 2007           Special Professor, Tokyo Institute of Technology

2002 –  Present      Member, California Nanosystems Institute

1995-  Present      Member, Jonsson Comprehensive Cancer Center, UCLA

1993-  Present      Member, Molecular Biology Institute, UCLA

Leadership Roles

2019 – Present     Leader, Quantum Nano Medicine Research Center, Kyoto University

2017 – Present     Special fellow, Japan Science and Technology Agency (JST-CRDS)

1996 –  2017           Director, Signal Transduction and Therapeutics Program Area, Jonsson Comprehensive Cancer Center, UCLA

2004 – 2017   Associate Director, Center for Global Mentoring, UCLA

2008 – 2010   Research Director, California NanoSystems Institute, UCLA

2004 – 2011          Vice Chair, Dept. of Microbiology, Immunology and Molecular Genetics

2004 – 2007  Co-group Leader, NanoBiotechnology, California NanoSystems Institute

1997 – 1999           Vice Chair, Joint Departments of Microbiology & Immunology/ Microbiology & Molecular Genetics, University of California, Los Angeles (UCLA)

1997                       Acting Chair, Department of Microbiology and Molecular Genetics, University of California, Los Angeles (UCLA)

1989- 1994            Established Investigator, American Heart Association

Editorial Board:

Journal of Biological Chemistry, Editorial Board, 1997-2002, 2008-2013

Since 2002, Prof. Tamanoi has been a series editor for The Enzymes published by Academic Press/Elsevier and published 20 books.

PUBLICATIONS

Prof. Tamanoi has >190 publications, of which I only selected a subset for listing below. Prof. Tamanoi has six publications together with Prof. Tsuneko Okazaki and/or her husband Prof. Reiji Okazaki. His publication list includes many articles in top-journals such as Nature, Cell (3x, 1x as last author), Science (last author), PNAS (23x, of which 6x as first and 10x as last author), Nature Genetics, Nature Cell Biology, Nature Chemical Biology, EMBO Journal (3x, 1x as last author), ACS Nano, and Small (5x, 2x as last author).

1. Tamanoi, F., Uchida, T., Egami, F. and Oshima, T. (1976) Synthesis of various phosphodiesters and phosphomonoesters with ribonuclease N1. J. Biochem. 80, 27-32.
2. Hirose, S., Okazaki, R. and Tamanoi, F. (1973) Mechanism of DNA chain growth. XI. Structure of RNA-linked DNA fragments of E. coli. J. Mol. Biol. 77, 501-517.
3. Okazaki, R., Okazaki, T., Hirose, S., Sugino, A., Ogawa, T., Kurosawa, Y., Shinozaki, K., Tamanoi, F., Seki, T., Machida, Y., Fujiyama, A. and Kohara, Y. (1975) Discontinuous replication in prokaryotic systems. In: DNA Synthesis and Its Regulation, Vol. III. (M. Goulian & P. Hanawalt, eds.; F. Fox series ed.) ICN-UCLA Symposium on Molecular and Cellular Biology, W.A. Benjamin, California, p.832.
4. Tamanoi, F., Okazaki, T. and Okazaki, R. (1977) Persistance of RNA attached to nascent short DNA pieces in Bacillus subtilis cells defective in DNA polymerase I. Biochem. Biophys. Res. Commun. 77, 290-297.
5. Tamanoi, F. and Okazaki, T. (1978) Uracil incorporation into nascent DNA fragments of thymine requiring mutant of B. subtilis 168. Proc. Natl. Acad. Sci. USA 75, 2195-2199.
6. Okazaki, T., Kurosawa, Y., Ogawa, T., Seki, T., Shinozaki, K., Hirose, S., Fujiyama, A., Kohara, Y., Machida, Y., Tamanoi, F. and Hozumi, T. (1979). Structure and metabolism of the RNA primer in the discontinuous replication of prokaryotic DNA. Cold Spring Harbor Symp. Quant. Biol. 43, 203-219.
7. Tamanoi, F., Machida, Y. and Okazaki, T. (1979) Uracil incorporation into nascent DNA by B. subtilis and E. coli. Cold Spring Harbor Symp. Quant. Biol. 43, 239-242.
8. Tamanoi, F., Saito, H., and Richardson, C.C. (1980) Physical mapping of primary and          secondary origins of bacteriophage T7 DNA replication. Proc. Natl. Acad. Sci. USA 77, 2656-2660.
9. Saito, H., Tabor, S., Tamanoi, F., and Richardson, C.C. (1980) Nucleotide sequence of the primary origin of bacteriophage T7 DNA replication: relationship to adjacent genes and regulatory elements. Proc. Natl. Acad. Sci. USA 77, 3917-3921.
10. Romano, L.J., Tamanoi, F. and Richardson, C.C. (1981) Initiation of DNA repication at the primary origin of bacteriophage T7 by purified proteins: requirements for T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 78, 4107-4111.
11. Deuring, R., Winterhoff, U., Tamanoi, F., Stabel, S., and Doerfler, W. (1981) Site of linkage between adenovirus type 12 and cell DNAs In hamster tumor line CLAC3. Nature 293, 5827, 81-84.
12. Tamanoi, F., and Stillman, B.W. (1982) Function of adenovirus terminal protein in the initiation of DNA replication. Proc. Natl. Acad. Sci. USA 79, 2221-2225.
13. Stillman, B.W., Tamanoi, F., and Mathews, M.B. (1982) Purification of an adenovirus coded DNA polymerase that is required for initiation of DNA replication. Cell 31, 613-623.
14. Tamanoi, F., and Stillman, B.W. (1983) Initiation of adenovirus DNA replication in vitro requires a specific DNA sequence. Proc. Natl. Acad. Sci. USA 80, 6446-6450.
15. Guggenheimer, R.A., Stillman, B.W., Nagata, K., Tamanoi, F. and Hurwitz, J. (1984) DNA sequences required for the in vitro replication of adenovirus DNA. Proc. Natl. Acad. Sci. USA 81, 3069-3073.
16. Fasano, O., Aldrich, T., Tamanoi, F., Taparowsky, E., Furth, M. and Wigler, M. (1984) Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc. Natl. Acad. Sci. USA 81, 4008-4012.
17. Tamanoi, F., Walsh, M., Kataoka, T., and Wigler, M. (1984) A product of yeast RAS2 gene is a guanine nucleotide binding protein. Proc. Natl. Acad. Sci. USA 81, 6924-6928.
18. Broek, D., Samiy, N., Fasano, O., Fujiyama, A., Tamanoi, F., Northup, J., and Wigler, M. (1985) Differential activation of yeast adenylate cyclase by wild-type and mutant RAS proteins. Cell 41, 763-769.
19. Fujiyama, A. and Tamanoi, F. (1986) Processing and fatty acylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 83, 1266-1270.
20. Fujiyama, A., Matsumoto, K., and Tamanoi, F. (1987) A novel yeast mutant deficient in the processing of ras proteins: Assessment of the effect of the mutation on processing steps. EMBO J. 6, 223-228.
21. Cobitz, A.R., Yim E.H., Brown, W.R., Perou, C.M. and Tamanoi, F. (1989) Phosphorylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 86, 858-862.
22. Finegold, A.A., Schafer, W.R., Rine, J., Whiteway, M., and Tamanoi, F. (1990) Common modifications of trimeric G proteins and ras protein: Involvement of polyisoprenylation. Science 249, 165-171.
23. Goodman, L.E., Judd, S.E., Farnsworth, C.C., Powers, S., Gelb, M.H., Glomset, J.A. and Tamanoi, F. (1990) Mutants of Saccharomyces cerevisiae defective in the farnesylation of ras proteins. Proc. Natl. Acad. Sci. USA 87, 9665-9669.
24. Xu, G., Lin, B., Tanaka, K., Dunn, D., Wood, D., Gesteland, R., Weiss, R. and Tamanoi, F. (1990) The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63, 835-841.
25. Tanaka, K., Lin, B.K., Wood, D.R. and Tamanoi, F. (1991) IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase activating protein (GAP). Proc. Natl. Acad. Sci. USA 88, 468-472.
26. Finegold, A.A., Johnson, D.I., Farnsworth, C.C., Gelb, M.H., Judd, S.R., Glomset, J.A. and Tamanoi, F. (1991) Protein geranylgeranyl transferase of Saccharomyces cerevisiae is specific for Cys-Xaa-Xaa-Leu motif proteins and requires the CDC43 gene product, but not the DPR1 gene product. Proc. Natl. Acad. Sci. USA 88, 4448-4452.
27. Golubic, M., Tanaka, K., Dobrowski, S., Wood, D., Tsai, M.H., Marshall, M., Tamanoi, F. and Stacey, D.W. (1991) The GTPase stimulatory activities of the neurofibromatosis type 1 and the yeast IRA2 proteins are inhibited by arachidonic acid. The EMBO J. 10, 2897-2903.
28. McNeel, D.G. and Tamanoi, F. (1991) Terminal region recognition factor 1, a DNA-binding protein recognizing the inverted terminal repeats of the pGKl linear DNA plasmids. Proc. Natl. Acad. Sci. USA 88, 11398-11402.
29. Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M. and Tamanoi, F. (1993) Identification of ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA 90, 2281-2285.
30. Diaz, M., Sanchez, Y., Bennett, T., Sun, C.R., Godoy, C., Tamanoi, F., Duran, A. and Perez, P. (1993) The Schizosaccharomyces pombe cwg2+ gene codes for the ß subunit of a geranylgeranyltransferase type I required for ß-glucan synthesis. The EMBO Journal. 12, 5245-5254.
31. Cohen, L., Mohr, R., Chen, Y-Y, Huang, M., Kato, R., Dorin, D., Tamanoi, F., Goga, A., Afar, D., Rosenberg, N. and Witte, O. (1994) Transcriptional activation of a novel ras-like    gene (kir) by oncogenic tyrosine kinases. Proc. Natl. Acad. Sci. USA 91, 12448-12452.
32. Mitsuzawa, H., Esson, K. and Tamanoi, F. (1995) Mutant farnesyltransferase ß subunit of           Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I ß subunit. Proc. Natl. Acad. Sci. USA 92, 1704-1708.
33. Scoles, D.R., Huynh, D.P., Morcos, P.A., Coulsell, E.R., Robinson, N.G.G., Tamanoi, F. and Pulst, S.M. (1998) Neurofibromatosis 2 tumor suppressor schwannomin interacts with bII-spectrin. Nature Genet. 18, 354-359.
34. Suzuki, N., Del Villar, K. and Tamanoi, F. (1998) Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells which are blocked by microtubule interfering agents.  Proc. Natl. Acad. Sci. USA 95, 10499-10504.
35. Suzuki, N., Urano, J. and Tamanoi, F. (1998) Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA 95, 15356-15361.
36. Guo, W., Tamanoi, F. and Novick, P. (2001) Spatial regulation of the exocyst complex by Rho1 GTPase. Nature Cell Biol. 3, 353-360.
37. Kato-Stankiewicz, J., Hakim, I., Zhi, G., Zhang, J., Serebriiskii, I., Guo, L., Edamatsu, H., Koide, H., Menon, S., Eckl, R., Sakamuri, S., Lu, V., Chen, Q., Agarwal, S., Baumbach, W.R., Golemis, E.A., Tamanoi, F. and Khazak, V. (2002) Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl. Acad. Sci. USA 99, 14398-14403.
38. Kho, Y., Kim, S.C., Jiang, C., Barma, D., Kwon, S.W., Cheng, J., Weinbaum, C., Tamanoi, F., Falck, J. and Zhao, Y. (2004) A novel tagging-via-substrate technology for detection and proteomics of farnesylated proteins.  Proc. Natl. Acad. Sci. USA 101, 12479-12484.
39. Gelb, M.H., Brunsveld, L., Hrycyna, C.A., Michaelis, S., Tamanoi, F., Van Voorhis, W.C. and Waldmann, H. (2006) Protein prenylation and associated modification: Opportunities for therapeutic intervention. Nature Chem. Biol. 10, 518-528.
40. Urano, J., Sato, T., Matsuo, T., Ohtsubo, Y., Yamamoto, M. And Tamanoi, F. (2007) point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells.  Proc. Natl. Acad. Sci. USA 104, 3514-3519.
41. Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S.G., Nel, A.E., Tamanoi, F. and Zink, J.I. (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS NANO 2, 889-896.
42. Jiang H, Song C, Chen CC, Xu R, Raines KS, Fahimian BP, Lu CH, Lee TK, Nakashima A, Urano J, Ishikawa T, Tamanoi F, Miao J. (2010) Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy. PNAS 107(25):11234-9.
43. Lu J, Liong M, Li Z, Zink J, Tamanoi F. (2010) Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 6:1794-805.
44. Ferris DP, Lu J, Gothard C, Yanes R, Thomas CR, Olsen JC, Stoddart JF, Tamanoi F, Zink JI. (2011) Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small. 7, 1816-1826.
45. Yanes RE, Tarn D, Hwang AA, Ferris DP, Sherman SP, Thomas CR, Lu J, Pyle AD, Zink JI, Tamanoi F. (2013) Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small 9, 697.
46. Croissant J, Chaix A, Mongin O, Wang M, Clement S, Raehm L, Durand JO, Hugues V, Blanchard-Desce M, Maynadier M, Gallud A, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Ferris DP, Tarn D, Zink JI.(2014) Two-photon-triggered drug delivery via fluorescent nanovalves (2014) Small 10, 1752-1755.
47. Hwang AA, Lu J, Tamanoi F, Zink J (2014) Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Small 11, 319-328.
48. Mai NXD, Birault A, Matsumoto K, Tan HKT, Intasa-ard SG, Morrison K, Thang PB, Doan TLH, Tamanoi F. (2020) Biodegradable periodic mesoporous organosilica (BPMO) loaded with daunorubicin: A promising nanoparticle-based anticancer drug. ChemMedChem 15, 1-8.
49. Tamanoi F, Matsumoto K, Doan TLH, Shiro A, Saitoh H. (2020) Studies on the exposure of gadolinium containing nanoparticles with monochromatic X-rays drive advances in radiation therapy. Nanomaterials 10, 1341.
50. Chinnathambi S, Tamanoi F. (2020) Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy. Pharmaceutics 12(9):890.
51. Nasimian A, Farzaneh P, Tamanoi F, Bathaie SZ. (2020) Cytosolic and mitochondrial ROS production resulted in apoptosis induction in breast cancer cells treated with crocin: The role of FOXO3a, PTEN and AKT signaling. Biochem Pharmacol 177: 113999.
52. Gisbert-Garzarán M, Lozano D, Matsumoto K, Komatsu A, Manzano M, Tamanoi F, Vallet-Regí M. (2021)  Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape. ACS Appl Mater Interfaces 13: 9656-9666.
53. Tamanoi, F., Chinnathambi, S., Laird, M., Komatsu, A., Birault, A., Takata, T., Doan, T.L.H, Mai, NXD, Raitano, A., Morrison, K., Suzuki, M., Matsumoto, K. (2021) Construction of boronophenylalanine-loaded biodegradable periodic mesoporous organosilica nanoparticles for BNCT cancer therapy. Int. J. Mol. Sci. 22, 2251.
54. Mai NXD, Dang YT, Ta HKT, Bae JS, Park S, Thang PB, Tamanoi F, Doan TLH. (2021) Reducing particle size of biodegradable nanomaterial for efficient curcumin loading. J. Mat. Res. 56, 3713-3722.
55. Mai NXD, Le UN, Nguyen LHT, Ta HTK, Van Nguyen H, Le TM, Phan TB, Nguyen LTT, Tamanoi F, Tan LH (2021) Facile synthesis of biodegradable mesoporous functionalized-organosilica nanoparticles for enhancing the anti-cancer efficiency of cordycepin. Micoroporous and Mesoporous Materials 315, 110913.
56. Higashi, Y., Matsumoto K, Saitoh H, Shiro A, Ma, Y., Laird, M., Chinnathambi, S., Birault, A., Doan, T.L.H., Yasuda, R., Tajima T, Kawachi, T., Tamanoi F. (2021) Iodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray. Sci Rep. 11: 13275.
57. Komatsu A, Matsumoto K, Yoshimatsu Y, Sin Y, Kubota A, Saito T, Mizumoto A, Ohashi S, Muto M, Noguchi R, Kondo T, Tamanoi F. (2021) The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine. Cells. 10, 2613.
58. Higashi, Y., Ikeda, S., Matsumoto, K., Satoh, S., Komatsu, A., Sugiyama, H., Tamanoi, F. (2022) Tumor accumulation of PIP-based KRAS inhibitor KR12 evaluated by the use of a simple, versatile chicken egg tumor model. Cancers 14, 951.